Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Akebia Therapeutics (AKBA)
NASDAQ:AKBA
Akebia Therapeutics (AKBA) Stock Price & Analysis
828 Followers
AKBA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.24 - $2.34
Previous Close$0.6
Volume22.05K
Average Volume (3M)2.27M
Market Cap
$119.55M
Enterprise Value$120.92M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-1.2
Beta0.91
Next Earnings
May 08, 2023EPS Estimate
-$0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding184,248,045
10 Day Avg. Volume1,071,309
30 Day Avg. Volume2,271,182
Standard Deviation0.28
R-Squared0.03
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)-1.00
Price to Sales (P/S)0.38
Price to Cash Flow (P/CF)10.50
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.51
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.83
Forecast
1Y Price Target
$1.25Price Target Upside110.97% Upside
Rating ConsensusHold
Number of Analyst Covering3
Akebia Therapeutics News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AKBA FAQ
What was Akebia Therapeutics’s price range in the past 12 months?
Akebia Therapeutics lowest stock price was $0.24 and its highest was $2.34 in the past 12 months.
What is Akebia Therapeutics’s market cap?
Currently, no data Available
When is Akebia Therapeutics’s upcoming earnings report date?
Akebia Therapeutics’s upcoming earnings report date is May 08, 2023 which is in 40 days.
How were Akebia Therapeutics’s earnings last quarter?
Akebia Therapeutics released its earnings results on Mar 09, 2023. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.183 by $0.143.
Is Akebia Therapeutics overvalued?
According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued.
Does Akebia Therapeutics pay dividends?
Akebia Therapeutics does not currently pay dividends.
What is Akebia Therapeutics’s EPS estimate?
Akebia Therapeutics’s EPS estimate is -$0.15.
How many shares outstanding does Akebia Therapeutics have?
Akebia Therapeutics has 184,248,050 shares outstanding.
What happened to Akebia Therapeutics’s price movement after its last earnings report?
Akebia Therapeutics reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.183. Following the earnings report the stock price went down -22.33%.
Which hedge fund is a major shareholder of Akebia Therapeutics?
Among the largest hedge funds holding Akebia Therapeutics’s share is Woodline Partners LP. It holds Akebia Therapeutics’s shares valued at N/A.
---
Akebia Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.25 (110.97% Upside)
$1.25 (110.97% Upside)
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $171.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-75.45%
12-Months-Change
Fundamentals
Return on Equity
-215.77%
Trailing 12-Months
Asset Growth
-33.05%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
---
Top 5 ETFs holding AKBA
Currently, no data available
Please return soon. This page is being updated.
Up to five ETFs with an Outperform Smart Score that hold AKBA. The ETFs are listed according to market value of AKBA within the ETF
---
---